Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B P Roques

Showing results (11-20 of 558) with videos related to

Pageof 56
Sort By:
Neuroscience Letters|May 13, 1998
Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in ratsO Valverde, B P Roques
FEBS Letters|January 20, 1997
Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in miceF Noble, B P Roques
Annales Pharmaceutiques Francaises|April 26, 2003
[Plusridisciplinary approaches to understand the neutoxic effects of Ecstasy]B P Roques, F Noble
Neuropeptides|October 3, 2002
Phenotypes of mice with invalidation of cholecystokinin (CCK(1) or CCK(2)) receptorsF Noble, B P Roques
Drug News & Perspectives|August 26, 2003
HIV-1 NCp7 as a target for the design of novel antiviral agentsS Druillennec, B P Roques
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1992
[Selective opioid agonists and inhibitors of enkephalin degradation enzymes: pharmacological and clinical values]F Noble, B P Roques
European Journal of Biochemistry|November 24, 1999
NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein VprK Wecker, B P Roques
Trends in Pharmacological Sciences|June 1, 1990
Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives?B P Roques, A Beaumont
Neuroscience Letters|February 9, 1995
Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphineF Noble, B P Roques
NIDA Research Monograph|January 1, 1995
Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addictionB P Roques, F Noble
Pageof 56

Showing results (11-20 of 558) with videos related to

Sort By:
Pageof 56
Neuroscience Letters|May 13, 1998
Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in ratsO Valverde, B P Roques
FEBS Letters|January 20, 1997
Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in miceF Noble, B P Roques
Annales Pharmaceutiques Francaises|April 26, 2003
[Plusridisciplinary approaches to understand the neutoxic effects of Ecstasy]B P Roques, F Noble
Neuropeptides|October 3, 2002
Phenotypes of mice with invalidation of cholecystokinin (CCK(1) or CCK(2)) receptorsF Noble, B P Roques
Drug News & Perspectives|August 26, 2003
HIV-1 NCp7 as a target for the design of novel antiviral agentsS Druillennec, B P Roques
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1992
[Selective opioid agonists and inhibitors of enkephalin degradation enzymes: pharmacological and clinical values]F Noble, B P Roques
European Journal of Biochemistry|November 24, 1999
NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein VprK Wecker, B P Roques
Trends in Pharmacological Sciences|June 1, 1990
Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives?B P Roques, A Beaumont
Neuroscience Letters|February 9, 1995
Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphineF Noble, B P Roques
NIDA Research Monograph|January 1, 1995
Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addictionB P Roques, F Noble
Pageof 56